The exchange offer's 98% minimum participation condition is the key near-term catalyst—if met, it eliminates near-term debt maturity risk but floods the float with shares. The FDA Pre-NDA meeting in mid-June is a binary event for seralutinib's regulatory path. Monitor the tender deadline (June 1 early tender, June 16 final) and the special meeting for stockholder approval of share authorization and reverse split. The PROSERA CT FRI data is supportive but exploratory; the FDA's view on a single-trial NDA is the real test.
Price Chart
Executive Summary
Gossamer Bio launched an exchange offer to swap up to $200M of 5.00% convertible notes due 2027 for $72M of new 7.50% secured notes due 2030, ~317.6M common shares, and up to 150M warrants, supported by holders of 75.2% of the existing notes via a transaction support agreement. The company also reported Q1 2026 financial results (revenue $17.0M, net loss -$46.7M), announced an FDA Pre-NDA Type B meeting for mid-June, and released positive exploratory CT FRI substudy results from the Phase 3 PROSERA trial. The exchange offer is the dominant event—it materially reduces debt but massively dilutes common equity, while the FDA meeting and imaging data provide a binary catalyst path.
Key Financial Metrics
Key Facts
- Exchange offer to swap up to $200M of 5.00% convertible notes due 2027 for $72M of new 7.50% secured notes due 2030, up to 317,647,058 common shares, and up to 150,000,000 warrants.
- Holders of 75.2% of existing notes have signed a transaction support agreement to tender; minimum participation condition of 98% of aggregate principal.
- Q1 2026 revenue from Chiesi collaboration was $17.0M (incl. $9.3M cost reimbursement), net loss -$46.7M ($0.20/share), cash $99.2M.
- FDA confirmed in-person Pre-NDA Type B meeting for mid-June 2026; NDA submission for seralutinib in PAH expected September 2026.
- PROSERA CT FRI substudy (n=162) showed statistically significant treatment effects across arterial, venous, and fibrosis parameters.
- Authorized shares to increase from 700M to 4B; reverse stock split range of 1:10 to 1:150 proposed.
- Estimated fees and expenses of ~$7.2M for the exchange offer.
Financial Impact
Debt reduction of $128M (from $200M to $72M) but massive dilution: up to 317.6M new shares + 150M warrants on a pre-offer share count of ~234M. Net loss widened to -$46.7M from -$36.6M YoY. Cash burn ~$37.7M in Q1.
Risk Factors
- Exchange offer may fail if <98% of noteholders tender, leaving the company with the full $200M debt maturity in 2027.
- Massive dilution from up to 317.6M new shares and 150M warrants could crush common stock price.
- FDA Pre-NDA meeting could result in a requirement for an additional trial, delaying or blocking NDA submission.
- Cash runway only into Q1 2027; further capital raises likely needed even if exchange offer closes.
- Reverse stock split (up to 1:150) signals potential Nasdaq delisting risk if share price remains low.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001728117-26-000037 |
| Document: 0001728117-26-000037-index-headers.html | 0001728117-26-000037 |
| Document: 0001728117-26-000037-index.html | 0001728117-26-000037 |
| Document: 0001728117-26-000037.txt | 0001728117-26-000037 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 17d ago | SC 13D/A | $9.31 | awaiting T+20 | — | $9.15 (+1.72%) |
Sep 28, 2026 27d ago | SC 13D/A | $11.58 | awaiting T+20 | — | $9.15 (+20.98%) |
Sep 22, 2026 4w ago | Institutional Cluster | $11.69 $9.58 | ▼ −18.05% | ▼ −17.49% | $9.15 (−21.73%) |
Sep 16, 2026 5w ago | 8-K | $11.94 $8.89 | ▼ −25.54% | ▼ −26.75% | $9.15 (−23.37%) |
Sep 11, 2026 6w ago | 8-K | $10.73 $9.31 | ▲ +13.23% | ▲ +15.10% | $9.15 (+14.73%) |
Sep 9, 2026 6w ago | 8-K | $0.1597 $0.1273 | ▼ −20.32% | ▼ −22.26% | $9.15 (+5629.49%) |
Aug 21, 2026 9w ago | 8-K | $0.1547 $0.1410 | ▲ +8.86% | ▲ +9.87% | $9.15 (−5814.67%) |
Aug 13, 2026 10w ago | 8-K | $0.1542 $0.1337 | ▼ −13.26% | ▼ −11.27% | $9.15 (+5833.85%) |
Jul 1, 2026 16w ago | 8-K | $0.1677 $0.1783 | ▼ −6.32% | ▼ −6.87% | $9.15 (−5356.17%) |
Jun 17, 2026 18w ago | 8-K | $0.1790 $0.1701 | ▲ +4.97% | ▲ +5.29% | $9.15 (−5011.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers